IPO Profile

Theravance Inc.
901 Gateway Boulevard, South San Francisco, California 94080
Tel: 650-808-6000
Web:
Ticker: THRX
Stock Exchange: Nasdaq
Shares Issued: 6,150,000.00
Price Offered: $16.00
Amount Raised: $72,800,000.00

Underwriters:
Merrill Lynch & Co.
Lehman Brothers
CS First Boston
Thomas Weisel Partners LLC


Company Description:
We are a biopharmaceutical company with a pipeline of product candidates that we discovered and expect to develop in collaboration with partners or on our own. In approximately seven years of operation, four product candidates discovered by us have advanced into clinical trials, two of which are currently in Phase 2. Further, we have six additional product candidates discovered by us in preclinical studies. We are focused on the discovery, development and commercialization of small molecule medicines for unmet medical needs across a number of therapeutic areas including respiratory disease, bacterial infections, overactive bladder and gastrointestinal disorders. We currently do not have any commercially available products and have not received any product revenue to date.